El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Documento de posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la enfermedad cardiovascular en los pacientes con enfermedad inflamatoria intestinal

dc.contributor.authorMarín Jiménez, Ignacio
dc.contributor.authorCarpio, Daniel
dc.contributor.authorHernández, Vicent
dc.contributor.authorMuñoz, Fernando
dc.contributor.authorZatarain Nicolás, Eduardo
dc.contributor.authorZabana, Yamile
dc.contributor.authorMañosa, Míriam
dc.contributor.authorRodríguez Moranta, Francisco
dc.contributor.authorBarreiro de Acosta, Manuel
dc.contributor.authorGutiérrez Casbas, Ana
dc.date.accessioned2025-07-08T10:45:19Z
dc.date.available2025-07-08T10:45:19Z
dc.date.issued2024-11-28
dc.date.updated2025-06-26T09:34:15Z
dc.description.abstractCardiovascular diseases (CVD) are the leading cause of death worldwide. Therefore, it is essential to understand their relationship and prevalence in different diseases that may present specific risk factors for them. The objective of this document is to analyze the specific prevalence of CVD in patients with inflammatory bowel disease (IBD), describing the presence of classical and non-classical cardiovascular risk factors in these patients. Additionally, we will detail the pathophysiology of atherosclerosis in this patient group and the different methods used to assess cardiovascular risk, including the use of risk calculators in clinical practice and different ways to assess subclinical atherosclerosis and endothelial dysfunction. Furthermore, we will describe the potential influence of medication used for managing patients with IBD on cardiovascular risk, as well as the potential influence of commonly used drugs for managing CVD on the course of IBD. The document provides comments and evidence-based recommendations based on available evidence and expert opinion. An interdisciplinary group of gastroenterologists specialized in IBD management, along with a consulting cardiologist for this type of patients, participated in the development of these recommendations by the Spanish Group of Work on Crohn's Disease and Ulcerative Colitis (GETECCU).
dc.format.extent33 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1578-9519
dc.identifier.urihttps://hdl.handle.net/2445/222106
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.gastrohep.2024.502314
dc.relation.ispartofGastroenterología y Hepatología, 2024, vol. 48, num. 5, p. 502314
dc.relation.urihttps://doi.org/10.1016/j.gastrohep.2024.502314
dc.rightscc by-nc-nd (c) Marín Jiménez, Ignacio et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMalaltia de Crohn
dc.subject.classificationColitis ulcerosa
dc.subject.classificationMalalties cardiovasculars
dc.subject.otherCrohn's disease
dc.subject.otherUlcerative colitis
dc.subject.otherCardiovascular diseases
dc.titleDocumento de posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la enfermedad cardiovascular en los pacientes con enfermedad inflamatoria intestinal
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
1-s2.0-S0210570524003273-main.pdf
Mida:
4.59 MB
Format:
Adobe Portable Document Format